GLP-1 rebound weight gain: what actually works after stopping

What did @therealdrleemd actually say?

Dr. Lee's pitch is straightforward: stopping a GLP-1 drug cold is a mistake, and switching to smaller or less frequent "maintenance doses" can preserve weight loss without the full cost. He frames it with an analogy, "you wouldn't stop your blood pressure medication just because it worked," and closes by inviting viewers to comment if interested, which is essentially a soft lead-generation ask on a regulated drug.

The video is short on specifics. He never names a drug, a dose range, or a protocol. He implies these maintenance doses are affordable and that they prevent the regain "undoing all your hard work." The clinical framing sounds reassuring, but the actual evidence for a defined maintenance dosing strategy is thinner than this video suggests.

Does the science back this up?

The core fear he's addressing is real and well-documented. The problem is that the evidence for informal "maintenance dosing" as a reliable solution is not nearly as solid as he implies.

The STEP 4 trial (Rubino et al., 2021, JAMA) is the clearest data point here. Participants who discontinued semaglutide after 20 weeks regained about two-thirds of their lost weight within a year. That confirms the biological dependency Dr. Lee is gesturing at. GLP-1 receptor agonists work while you take them. When you stop, appetite-regulating hormones shift back, and weight returns for most people.

But the evidence for a specific "maintenance dose" strategy, meaning a deliberately reduced dose to sustain results long-term, is sparse. There is no large randomized trial establishing that half-doses or extended dosing intervals reliably preserve weight loss. Some clinicians use this approach clinically, but it is not FDA-approved protocol and the data backing it is largely observational or anecdotal. Presenting it as a clean solution overstates what we actually know.

What did they get wrong (or right)?

He got the big picture right. GLP-1 drugs are closer to ongoing treatments than temporary fixes, and the blood pressure medication analogy is actually a fair one. Obesity is a chronic condition with a physiological basis, and treating it episodically has poor outcomes. That framing deserves credit.

Where he goes wrong is in the confidence. Saying "here's exactly what you should do" and calling maintenance doses a solved, affordable option glosses over real uncertainties. First, individual response to lower doses varies significantly. Second, compounded versions of semaglutide or tirzepatide, which are likely what he is referring to when he mentions cost, are not equivalent to FDA-approved brand-name drugs. Assuming they are is a meaningful clinical leap. Third, "maintenance doses" is not a standardized term with regulatory or clinical consensus behind it. It means different things to different prescribers.

The call to "comment below if you're interested" also deserves scrutiny. Soliciting interest in a specific drug protocol via TikTok comments is not how responsible prescribing works.

What should you actually know?

If you have stopped a GLP-1 and are worried about regaining weight, that concern is clinically legitimate. The STEP 1 trial extension (Wilding et al., 2022, Nature Medicine) found that most participants regained substantial weight after stopping semaglutide, reinforcing that these drugs address a chronic, ongoing condition rather than a temporary one.

Continuing at a lower dose under proper medical supervision is a conversation worth having with a licensed prescriber who knows your full history. It is not something to decide based on a TikTok comment thread. Dose adjustments for GLP-1 medications should account for your baseline weight, metabolic response, side effect profile, and whether you are using a branded or compounded product, since those are not interchangeable from a regulatory or quality-assurance standpoint.

The honest answer is that long-term weight management after GLP-1 therapy is still an evolving area. There is no universally proven off-ramp strategy yet. Anyone telling you otherwise is ahead of the evidence.